Bingley

R.J. O'Brien Establishes New London-Based Global Metals Team

Retrieved on: 
Wednesday, September 21, 2022
Marchant, DMA, ICAP, Contract for difference, CME, IBS, Industry, CME Group, Bingley, London Metal Exchange, LME, Bear Stearns, EMEA, Dresdner Bank, Leadership, Bradley, Non-bank financial institution, Human, Multimedia, Metal, Category, BGC, Financial services, Associate

CHICAGO and LONDON, Sept. 21, 2022 /PRNewswire/ -- Chicago-based R.J. O'Brien & Associates (RJO), the oldest and largest independent futures brokerage and clearing firm in the United States, today announced that its London-based affiliate, R.J. O'Brien Limited (RJO Limited), has hired a new, highly experienced five-person metals team. Co-led by metals market veterans Bradley Marchant and Steven Bingley, the team will provide institutional clients globally with trade execution and clearing services, specializing in the world's leading metals markets – the London Metal Exchange (LME) and CME Group.

Key Points: 
  • Marchant, Bingley and their team have worked together for the past eight years, providing trade execution in the base metals markets.
  • At RJO Limited, the team will offer services including voice brokerage and direct market access (DMA) in base, precious and non-ferrous metals to a wide range of clients, including physical metals traders, asset managers, hedgers, producers and high-frequency traders.
  • Mark Phelps, Managing Director, EMEA for RJO Limited, said: "We are delighted to bring on such a well-established and respected team within the metals space under the leadership of Bradley and Steven.
  • Other members of the new RJO metals team are Joe Gregory, Martin Trott and Grant Gibbons, who have a combined 76 years of experience in the industry.

R.J. O'Brien Establishes New London-Based Global Metals Team

Retrieved on: 
Wednesday, September 21, 2022
Marchant, DMA, ICAP, Contract for difference, CME, IBS, Industry, CME Group, Bingley, London Metal Exchange, LME, Bear Stearns, EMEA, Dresdner Bank, Leadership, Bradley, Non-bank financial institution, Human, Metal, Category, BGC, Financial services, Associate

CHICAGO and LONDON, Sept. 21, 2022 /PRNewswire/ -- Chicago-based R.J. O'Brien & Associates (RJO), the oldest and largest independent futures brokerage and clearing firm in the United States, today announced that its London-based affiliate, R.J. O'Brien Limited (RJO Limited), has hired a new, highly experienced five-person metals team. Co-led by metals market veterans Bradley Marchant and Steven Bingley, the team will provide institutional clients globally with trade execution and clearing services, specializing in the world's leading metals markets – the London Metal Exchange (LME) and CME Group.

Key Points: 
  • Marchant, Bingley and their team have worked together for the past eight years, providing trade execution in the base metals markets.
  • At RJO Limited, the team will offer services including voice brokerage and direct market access (DMA) in base, precious and non-ferrous metals to a wide range of clients, including physical metals traders, asset managers, hedgers, producers and high-frequency traders.
  • Mark Phelps, Managing Director, EMEA for RJO Limited, said: "We are delighted to bring on such a well-established and respected team within the metals space under the leadership of Bradley and Steven.
  • Other members of the new RJO metals team are Joe Gregory, Martin Trott and Grant Gibbons, who have a combined 76 years of experience in the industry.

Emerald Health Therapeutics Appoints Moe Jiwan as Chief Operating Officer

Retrieved on: 
Tuesday, May 4, 2021
Bingley, Emerald Group Publishing, OTC Markets Group, XC2, Emerald, Publishing

b'Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald")\xc2\xa0has appointed Mr. Moe Jiwan as Chief Operating Officer effective May 10th.\nMr.

Key Points: 
  • b'Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald")\xc2\xa0has appointed Mr. Moe Jiwan as Chief Operating Officer effective May 10th.\nMr.
  • Before joining Emerald, he served in senior leadership positions, including chief information officer and chief customer officer, for established cannabis and health companies, including senior roles at TerrAscend Corp and Shopper\'s Drug Mart.
  • We wish them the best in their new endeavors," said Mr. Riaz Bandali, President & Chief Executive Officer of Emerald.
  • Moe has a well-rounded perspective on the strategy and execution necessary for the next phase of Emerald\'s redefined growth plan.

Emerald Health Therapeutics Terminates Consulting and Loan Agreements

Retrieved on: 
Thursday, July 16, 2020
Bingley, Emerald Group Publishing, Second Life, Video games, Operating systems

VANCOUVER, July 15, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has terminated certain related party agreements pertaining to consulting services and a loan facility.

Key Points: 
  • VANCOUVER, July 15, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has terminated certain related party agreements pertaining to consulting services and a loan facility.
  • Emerald Health Sciences Inc. ("EHS"), a control person of Emerald, and Emerald entered into an independent contractor agreement on May 1, 2015, as amended from time to time (the Consulting Agreement), and a loan agreement on August 25, 2015, as amended from time to time (the Loan Agreement).
  • We are very pleased with our progress to systematically rationalize, restructure and/or terminate agreements, in order to only focus on initiatives that will provide commercial and financial value to Emerald Health Therapeutics in the future, said Riaz Bandali, President and CEO of Emerald.
  • After the termination of these three agreements, Emerald Health Therapeutics has only one remaining related-party agreement with an Emerald Health Sciences entity.

Emerald Holding, Inc. Announces Temporary Suspension of Quarterly Dividend

Retrieved on: 
Friday, March 20, 2020
Software, Technology, Data management, Bingley, Emerald Group Publishing, Dividend, Publishing

The Board of Directors will re-assess the dividend suspension throughout the year to determine, in light of facts and circumstances at that time, whether and when to reinstate the dividend.

Key Points: 
  • The Board of Directors will re-assess the dividend suspension throughout the year to determine, in light of facts and circumstances at that time, whether and when to reinstate the dividend.
  • Taken together, we believe these are the right actions to position Emerald to successfully weather this challenging environment.
  • Emerald is a leader in building dynamic, market-driven business-to-business platforms that integrate live events with a broad array of industry insights, digital tools, and data-focused solutions to create uniquely rich experiences.
  • As true partners, we at Emerald strive to build our customers businesses by creating opportunities that inspire, amaze, and deliver breakthrough results.

Emerald Health Therapeutics Closes Final Tranche Prospectus Sale

Retrieved on: 
Saturday, February 15, 2020
Bingley, Emerald Group Publishing, Publishing

VANCOUVER, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has closed the final tranche of its $3,000,000 prospectus offering (the Offering), announced in its news release dated January 6, 2020.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has closed the final tranche of its $3,000,000 prospectus offering (the Offering), announced in its news release dated January 6, 2020.
  • Pursuant to this final closing, Emerald has issued an aggregate of 2,748,276 units of Emerald (each, a "Unit") at a price of $0.29 per Unit for total gross proceeds of $797,000.
  • Each Unit consists of one common share of Emerald and one common share purchase warrant (each, a "Warrant").
  • Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with recreational and wellness-oriented cannabis products.

Emerald Health Therapeutics Closes $2.2 Million Prospectus Sale

Retrieved on: 
Friday, February 7, 2020
Bingley, Emerald Group Publishing, Publishing

VANCOUVER, British Columbia, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has closed the first tranche of its $3,000,000 prospectus offering (the Offering) announced in its news release dated January 6, 2020.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF) has closed the first tranche of its $3,000,000 prospectus offering (the Offering) announced in its news release dated January 6, 2020.
  • Emerald wishes to clarify that the Debt represented amounts owed by Emerald to a related party under a previously disclosed hemp supply agreement pursuant to which Emerald received approximately 135,000 kg of product.
  • Emerald also announces that Thierry Schmidt has is no longer the Chief Commercialization Officer of Emerald.
  • Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with recreational and wellness-oriented cannabis products.

Emerald Health Therapeutics Closes Initial Tranche of Private Placement

Retrieved on: 
Tuesday, December 31, 2019
Bingley, Emerald Group Publishing, Publishing

VANCOUVER, British Columbia, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF), announced today that it has closed the initial tranche of a private placement which was announced on December 16, 2019.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (Emerald) (TSXV: EMH; OTCQX: EMHTF), announced today that it has closed the initial tranche of a private placement which was announced on December 16, 2019.
  • Emerald has closed the initial tranche (the "Initial Tranche") of its previously announced non-brokered private placement (the "Private Placement") for gross proceeds of $1,500,153.
  • Pursuant to the closing of the Initial Tranche, Emerald issued 5,172,942 units (each, a "Unit") at an issue price of $0.29 per Unit.
  • All Units sold pursuant to the Initial Tranche were purchased by Emerald Health Sciences Inc. ("Sciences"), a control person of Emerald, and certain directors and officers of Emerald.

Emerald Expositions Announces Leadership Transition

Retrieved on: 
Monday, December 9, 2019
Professional services, Marketing, Communications, Other Professional Services, Consulting, Other Communications, Articles, Business, Bingley, Emerald Group Publishing, Pharmaceutical industry, Chief operating officer

Emerald Expositions Events, Inc. (NYSE:EEX) (Emerald or the Company) today announced that Sally Shankland has made the decision, for personal health reasons, to step down from her position as President and Chief Executive Officer at the end of the year and will transition to the new role of Executive Director and Senior Advisor.

Key Points: 
  • Emerald Expositions Events, Inc. (NYSE:EEX) (Emerald or the Company) today announced that Sally Shankland has made the decision, for personal health reasons, to step down from her position as President and Chief Executive Officer at the end of the year and will transition to the new role of Executive Director and Senior Advisor.
  • We look forward to her continued involvement in the business and wish her every success in improving her health.
  • Prior to joining Emerald, Mr. Field was COO of UBM Americas, delivering events and marketing services in the technology, fashion, licensing, advanced manufacturing, construction, healthcare, and pharmaceutical industries.
  • Emerald is a leading operator of business-to-business trade shows in the United States.